AngioDynamics, Inc. (NASDAQ:ANGO) medical instruments manufacturer and supplier, is expected to report first quarter earnings results, before market open, on Tuesday 29th September 2020.
Analysts polled by Thomson Reuters anticipate first quarter loss of $ 0.07 per share from revenue of $ 65.10 million.
Looking ahead, the full year loss are expected at $ 0.1 per share on the revenues of $ 274.48 million.
Previous Quarter Performance
AngioDynamics, Inc. came out with loss for the fourth quarter of $ 0.06 per share, from the revenue of $ 58.33 million. The quarterly revenues down 39.43 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.06 per share from $ 64.30 million in revenue. The top line results fell short of analysts by $ 5.97 million or 9.28 percent.
Stock Performance
Shares of AngioDynamics, Inc. traded up $ 0.62 or 6.17 percent on Monday, reaching $ 10.67 with volume of 547.80 thousand shares. AngioDynamics, Inc. has traded high as $ 10.92 and has cracked $ 10.11 on the downward trend
According to the previous trading day, closing price of $ 10.67, representing a 34.36 % increase from the 52 week low of $ 7.48 and a 46.26 % decrease over the 52 week high of $ 18.70.
The company has a market capital of $ 404.11 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
AngioDynamics, Inc. will be hosting a conference call at 8:00 AM eastern time on 29th September 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.angiodynamics.com
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors.
